Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Jan. 23];9(6):s707. Available from: https://skin.dermsquared.com/skin/article/view/3859